

BAYLOR COLLEGE OF MEDICINE
CURRICULUM VITAE
HANA EL SAHLY, M.D.

I. GENERAL BIOGRAPHICAL INFORMATION

A. Personal

1. Name: Hana M. El Sahly
2. Citizenship: USA

B. Education (include institution/location, degree, and dates of attendance)

1. Undergraduate Education: American University of Beirut, Bachelor of Science, 1987-1990
2. Medical Education: American University of Beirut, School of Medicine, Doctor of Medicine, 1990-1994
3. Postgraduate Training:
Internal Medicine Residency Program, University of Connecticut, 1995-1998
Infectious Diseases Fellowship Program, Baylor College of Medicine, 1998-2001

C. Academic Appointments (include institution, title and dates of appointment)

1. Current Faculty Position(s)
Assistant Professor, Department of Pathology, Baylor College of Medicine, July 2001-June 2004
Assistant Professor, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, July 2004-June 2015 (tenure track since 2010)
Associate Professor (with Tenure), Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, July 2015-2021
Professor (with tenure), Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, April 2021-Present
2. Previous Faculty Position(s) at Other Institutions
NA
3. Current Courtesy Faculty Appointments at Other Institutions
NA

D. Other advanced training/experience (include locations, dates and sources of support)

1. Formal Sabbatical Leave
NA
2. Other Specialized Training Following Academic Appointment
How is the health science education tackling the opioid epidemic? An International Academy of Medical Sciences Education winter 2020 seminar series

E. Other information

1. Honors or Awards
 - Graduated with Distinction in Biology (B.S., 1990)
 - Graduated with Distinction in Medical School (M.D., 1994)
 - Offered Chief Resident position at the University of Connecticut
 - Second prize winner, Baylor Housestaff Research Symposium, 1999
 - Certificate of Excellence in Reviewing, Elsevier Publishing, 2013
 - First prize winner, Baylor Housestaff Research Symposium, 2014

- Outstanding Contribution in Reviewing, from the Editors of Journal of Infection, March 2015
- Fellow of the Infectious Diseases Society of America, 2016
- December 2020 Paper of the Month, Oligonucleotide Therapeutics Society, University College London, UK (Reference #72 from Dr. El Sahly’s publications below)
- Champion of diversity, equity and inclusion, National Diversity and Leadership Conference, 2021
- Michael E. Debakey Excellence in Research Award, 2021
- Ben Qurrah Award, National Arab America Medical Association, 2023
- Editor’s Choice Paper “Dean Follmann,...**Hana M. El Sahly**”. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial”. Open For Infect Dis (in press)
- Editor’s Choice Paper: Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case. Open For Infect Dis (in press)

2. Board Eligibility/Certification

Board Certified in Internal Medicine, 1998

Board Certified in Infectious Diseases, 2001, 2012

3. Other Non-academic Positions

NA

II. RESEARCH INFORMATION

A. Research Support (provide the following information for each project)

1. Current

Vaccine and Treatment Evaluation unit

Grant: National Institute of Health 1UM1AI148575-01

Role: Principal Investigator

Effort: 3.0 calendar months

Dates: 12/11/19-11/30/26

Total Direct: base funds of \$2,661,176

Adaptive COVID-19 Treatment Trial

Grant: National Institutes of Health, 3UM1AI148575-01S1

Role: BCM site PI (overall PI: John Beigel, NIH)

Effort: 3.0 calendar months

Dates: 03/13/20 – 11/30/2022

Total Direct: \$1,757,571

Phase 3 COVID-19 vaccine efficacy clinical trials (MODERNA vaccine)

Grant: National Institutes of Health, 3UM1AI148575-01S2

Role: BCM site PI and National co-chair

Effort: 2.4 calendar months

Dates: 07/13/20 – 11/30/2022

Total Direct: \$7,633,473

SARS-COV-2 Seroprevalence Study

Grant: National Institutes of Health 3UM1AI148575-02S1

Role: BCM VTEU PI, study PI at BCM: Dr. Amos
Effort: 0.24 calendar months
Dates: 12/18/2020-12/18/2022
Total Direct Year 1: \$1,097,662

Phase 3 COVID-19 vaccine efficacy clinical trials (Novavax vaccine)
Grant: National Institutes of Health, 3UM1AI148575-02S4
Role: BCM VTEU PI, study PI at BCM: Drs. CM Healy and JA Whitaker
Effort: 0.6 calendar months
Dates: 12/23/20 – 11/30/2021
Total Direct: \$ 1,634,250

Phase 2/3 trial of COVID-19 vaccine in children (moderna)
Grant: National Institutes of Health, 3UM1AI148575-02S5
Role: BCM VTEU PI, and Co-I; study PI at BCM: Dr. E. Nicholson
Effort: 0.12 calendar months
Dates: 5/19/2021-11/30/2022
Total Direct: \$ 965,850

Phase 1 trial of COVID-19 Chimpanzee Adenovirus and Self-Amplifying mRNA vaccine
Grant: National Institutes of Health, 3UM1AI148575-02S6
Role: BCM VTEU PI, and co-I; Study PI at BCM: Dr. JA Whitaker
Effort: 0.12 calendar months
Dates: 5/20/2021-11/30/2022
Total Direct: \$ 277,728

A Phase 1/2 study of delayed heterologous SARS-CoV-2 vaccine dosing (boost) after receipt of EUA vaccines.
Grant: National Institutes of Health, 3UM1AI148575-02S7
Role: BCM VTEU PI, and co-I; Study PI at BCM: Dr. RL Atmar
Effort: 0.12 calendar months
Dates: 7/14/2021-11/30/2025
Total Direct: \$ 2,130,999

Observational, prospective cohort study of the immunogenicity and safety of SARS-CoV-2 vaccines administered during pregnancy or post-partum and evaluation of antibody transfer and durability in infants
Grant: National Institutes of Health, 3UM1AI148575-02S8
Role: BCM VTEU PI, and co-I; Study PI at BCM: Dr. F. Munoz
Effort: 0.12 calendar months
Dates: 7/15/2021-11/30/2024
Total Direct: \$192,557

COVID-19 Adaptive Variant Immunologic Landscape Trial or Covail Trial
Grant: Leidos subcontract from National Institutes of Health 22CTA-DM0002
Role: BCM VTEU PI, Study PI at BCM: Dr. J. Whitaker
Effort: 0.60 calendar months
Dates: 04/20/22-10/19/25
Total Direct Costs: \$700,161

A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Vaccine

Grant: Leidos subcontract from National Institutes of Health DMID 22-0020
Role: Principal Investigator
Effort: 1.20 calendar months
Dates: 08/12/2022-12/23/2023
Total Direct Costs: \$318,281

Randomized Participant-and Investigator-Blinded Trial to Compare the Clinical Efficacy of Recombinant Influenza Vaccine to Standard Dose Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years in the United States (RAIVEN)
Grant: Centers for Disease Control (CDC)
Role: Principal Investigator
Effort: 1.20 calendar months
Dates: 01/01/2023-12/31/2023
Total Direct Costs: \$394,392

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) COVID 19 SUPPLEMENT
Contract: National Institutes of Health, 3UM1A1148684-01S1
Role: Co-Investigator (Overall PI: David Stephens, Emory)
Effort: 2.4 calendar months
Dates: 3/13/20-11/30/20
Total Direct: \$40,126

Vaccine and Treatment Evaluation Unit
Contract: National Institutes of Health, contract # HHSN272201300015I
Role: Principal Investigator
Effort: 1.2 calendar months
Dates: 04/01/2016 -09/18/2023
Total Direct Costs: minimum of \$100,000 to a maximum of \$619,069,746

A proof of concept, Randomized Controlled Study of Tuberculosis Immunization with BCG to Prevent Infection in Healthy Adults (TIPI trial)
Grant: Department of Defense HU0001-17-2-0023
Role: Co-Investigator (PI: Naomi Aronson)
Effort: 0.6 Calendar months
Dates: 01/15/2023-02/28/2025
Total Direct Costs: \$725,070

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
Grant: Emory subcontract from National Institutes of Health
Role: Principal Investigator
Effort: 1.20 calendar months
Dates: 02/08/2023-11/30/2023
Total Direct Costs: \$12,409

2. Completed

Evaluation of control measures against diseases other than AIDS
Contract: National Institutes of Health, N01-AI-80002

Role: Co-Investigator (Contract PI: W. Keitel)
Effort: 0.5 calendar month
Dates: 11/01/2007-12/31/2017
Total Direct Costs: \$20,976,559

HVTN505: Evaluation of the efficacy of a new HIV vaccine regimen (Sub-award)
Grant: National Institutes of Health, UM1 AI068614
Role: Sub-award PI (Grant PI: L. Corey)
Effort: 0.1 calendar months
Dates: 06/01/2010-11/30/2017
Total Direct Costs: \$634,657

RSV-E-301: A study to evaluate an RSV-F vaccine in older adults
Grant: Novavax, Inc.
Role: PI
Effort: 1.1 calendar months
Dates: October 2015-October 2016
Estimated Total Direct Costs: \$499,557

Anthrax vaccine adsorbed (AVA), human reactogenicity and immunogenicity trial to address a change
in route of administration and dose reduction
Grant: Centers for Disease Control and Prevention, CDC-200-2000-10063
Role: Co-Investigator (Grant PI: W. Keitel)
Effort: 2.4 calendar months
Dates: 2001-2010
Total Direct Costs: \$2,944,139

DMID 04-037: Phase 1, double-blinded, placebo-controlled dose-escalation study of the safety and
reactogenicity of *Francisella tularensis* live vaccine strain (LVS) administered by the scarification
and subcutaneous routes
Contract: National Institutes of Health, N01-AI-25465
Role: PI
Effort: 1.2 calendar months
Dates: 2004-2008
Total Direct Costs: \$609,715

DMID 04-059: Phase 1, double-blinded, placebo-controlled dosage-escalation study of the safety and
immunogenicity of EBA-175 RII-NG malaria vaccine administered intra-muscularly
Contract: National Institutes of Health, N01-AI-25465
Role: PI
Effort: 1.2 calendar months
Dates: 2005-2009
Total Direct Costs: \$311,121

Comparison of the immunogenicity, safety and reactogenicity of Flublok™, trivalent recombinant
baculovirus-expressed hemagglutinin influenza vaccine, to a licensed egg-grown influenza vaccine
in ambulatory elderly adults
Grant: Protein Sciences Corporation, PSC03
Role: PI
Effort: 1.2 calendar months
Dates: 2006-2007
Total Direct Costs: \$288,649

Evaluation of the immunogenicity, safety, reactogenicity, efficacy, effectiveness and lot consistency of FluBIØk™ trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine in healthy adults aged 18 to 49

Grant: Protein Sciences Corporation, PSC04

Role: PI

Effort: 1.2 calendar months

Dates: 2007-2008

Total Direct Costs: \$200,058

DMID 05-078: A phase I/II study of the safety and immunogenicity of a recombinant human parvovirus B-19 vaccine

Contract: National Institutes of Health, N01-AI-25465

Role: PI

Effort: 1.2 calendar months

Dates: 2007-2011

Total Direct Costs: \$153,188

Susceptibility of *Mycobacterium tuberculosis* clinical isolates to Moxifloxacin

Grant: National Institutes of Health, R03 AI074647

Role: PI

Effort: 1.2 calendar months

Dates: 09/01/2007-08/31/2009

Total Direct Costs: \$100,000

A randomized, observer-blind, active-controlled Phase III study to demonstrate the superior efficacy of GSK biologicals' adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix™

Grant: GlaxoSmithKline Biologics, 106372 FLU NG-006

Role: PI

Effort: 1.2 calendar months

Dates: 2008-2010

Total Direct Costs: \$110,029

DMID 09-0073: A phase II study in HIV-seropositive adults to assess the safety and immunogenicity of an unadjuvanted Novartis H1N1 influenza vaccine administered at two dose levels

Contract: National Institutes of Health, N01-AI-80002

Role: PI

Effort: 1.2 months

Dates: 2009-2012

Total Direct Costs: \$257,233

DMID 09-0002: Comparison of the safety and immunogenicity of lyophilized Imvamune® (1X10⁸ TCID₅₀) versus liquid formulation Imvamune® (1X10⁸ TCID₅₀) administered by the subcutaneous route and a lower dose liquid formulation Imvamune® (2X10⁷ TCID₅₀) administered by the intradermal route in healthy vaccinia-naïve individuals

Contract: National Institutes of Health N01-AI-80002

Role: PI

Effort: 1.2 calendar months

Dates: 2010-2013

Total Direct Costs: \$318,758

DMID 11-0034: A phase IIB, open-label, dose ranging study of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Contract: National Institutes of Health, N01-AI-80002

Role: PI

Effort: 1.8 calendar months

Dates: 09/19/2011-09/18/2015

Total Direct Costs: \$651,466

DMID 11-0021: A phase II, randomized, open label study to evaluate the safety and immunogenicity of Imvamune® using three immunization schedules and two modes of delivery

Contract: National Institutes of Health, N01-AI-80002

Role: PI

Effort: 2.4 calendar months

Dates: 09/19/2011-08/27/2015

Total Direct Costs: \$440,816

Phase II clinical trial to evaluate the safety and immunogenicity of Panblok™ at three dose levels adjuvanted with a stable oil-in-water-emulsion

Grant: Protein Sciences Corporation, PSC25

Role: PI

Effort: 0.6 calendar months

Dates: 2012-2013

Total Direct Costs: \$201,336

DMID 13-0034: A phase II randomized, partially-blinded, controlled trial in healthy adults aged 65 years and older to assess the safety, reactogenicity, and immunogenicity of an MF59-adjuvanted, monovalent inactivated influenza A/H7N9 virus vaccine administered intramuscularly at different intervals and dosages

Contract: National Institutes of Health, N01-AI-80002

Role: PI

Effort: 2.4 calendar months

Dates: 06/01/2014-01/31/2017

Total Direct Costs: \$391,853

B. National Scientific Participation

1. Editorial activities

Associate Editor, the *New England Journal of Medicine Journal Watch* 2019-2022

Deputy Editor, the *New England Journal of Medicine Journal Watch* 2022-

Ad hoc reviewer for the *American Journal of Tropical Medicine and Hygiene*, *Clinical Infectious Diseases*, *Clinical Therapeutics*, *Expert Reviews in Infectious Diseases*, *Infection and Drug Resistance*, *International Journal of Tuberculosis and Lung Diseases*, *Journal of Infection*, *Tuberculosis Research and Treatment*, *Vaccine*, *Open Forum Infectious Diseases*, *NPG Vaccines*, *The New England Journal of Medicine*, *JAMA*, *Lancet Infectious Diseases*, *The Lancet*, *Clinical Microbiology and Infection*

2. Review Panels and Other

a. Scientific Review

Reviewer, Loan Repayment Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health; 2008
Reviewer, Scientific Review Program, National Institute of Allergy and Infectious Diseases; 2010
Reviewer, Scientific Review Program, National Institutes of Health, P01 application “Towards A Universal Influenza Vaccine”; 2012
Reviewer, Influenza pre-applications, US Army Medical Research and Materiel Command-
Congressionally Directed Medical Research Programs, 2016
Reviewer and panel member, FY18 Congressionally Directed Medical Research Programs (CDMRP),
Peer Reviewed Medical Research Program (PRMRP), 2018
Reviewer and panel member, FY21 Congressionally Directed Medical Research Programs (CDMRP),
Flavivirus Vaccine Research Peer Review Panel, 2020
Chair and panel member, Special Emphasis Panel, RFA-AI-19-045 Clinical Trials Units for NIAID
Networks (UM1), Focus on International HIV/AIDS Clinical trials Units, 2020
Reviewer, Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section,
Division of AIDS, Behavioral and Population Sciences, NIH, 2022
Reviewer and panel member, “Vaccine and MAb development for Pandemic Preparedness against
Bunya-, Paramyxo- and Picornaviruses”, NIAID, NIH, 2023

b. Data and Safety Monitoring Board

Member, Safety Monitoring Committee, National Institutes of Health-sponsored vaccine clinical trial
05-0011; 2006
Member, Safety Monitoring Committee, National Institutes of Health-sponsored vaccine clinical trial
08-0009; 2009
Member, Data Safety Monitoring Board, Protein Sciences Corporation vaccine clinical trial PSC-22;
2010
Member, Safety Monitoring Committee, National Institutes of Health-sponsored study DMID 10-0043;
2011
Member, Safety Monitoring Committee, National Institutes of Health-sponsored study DMID 11-0007;
2011
Member, Safety Monitoring Committee, National Institutes of Health sponsored study DMID 13-0087;
2014
Member, Safety Monitoring Committee, Mercia Pharma Inc-sponsored study NOVA MAS-1; 2015-
2019
Chair, Safety Monitoring Committee, National Institutes of Health sponsored study DMID 16-0088;
2018-2019
Chair, Safety Monitoring Committee, National Institutes of Health sponsored study DMID 18-0006;
2019-Present
Chair, Safety Monitoring Committee, National Institutes of Health study DMID 22-0027; 2023-Present

c. International Scientific Participation

Reviewer, Tuberculosis Research, South African Medical Research Council; 2011
Reviewer, evaluation of applications sent in response to the Italian Ministry of Health Call for Grants;
2013
Scientific Reviewer, World Health Organization, Phase I Clinical Trial of H7N9 inactivated influenza
vaccine; 2014
Reviewer, World Health Organization, Protocol: “A phase I, double-blinded, randomized, placebo-
controlled, study to examine the safety and immunogenicity of a seasonal trivalent inactivated split

virion influenza vaccine (IVACFLU-S) produced by IVAC in healthy adult volunteers in Vietnam”, 2015

Reviewer, abstract submission to the 46th Union World Conference on Lung Health, Cape Town, South Africa, 2015

Scientific Grant Reviewer, Wellcome Trust DBT, Biomedical Research Fellowship Program for India, 2016

Reviewer, abstract submission to the 47th Union World Conference on Lung Health, Liverpool, United Kingdom, 2016

Reviewer, abstract submissions, IDWeek, Infectious Diseases Society of America, October 2016

Reviewer, abstract submission to the 48th Union World Conference on Lung Health, Guadalajara, Mexico, 2017

Member, IDweek Program Planning Committee, 2017-Present

Co-Chair, Pre-meeting Tuberculosis Workshop, Infectious Diseases Society of America, IDweek 2016-109

Reviewer, abstract submissions, IDWeek, Infectious Diseases Society of America, October 2017

Reviewer, abstract submission to the 48th Union World Conference on Lung Health, The Hague, The Netherlands, 2018

Reviewer, abstract submissions, IDWeek, Infectious Diseases Society of America, October 2018

Reviewer, abstract submission to the 49th Union World Conference on Lung Health, Hyderabad, India, 2019

Reviewer, abstract submissions, IDWeek, Infectious Diseases Society of America, October 2019

Moderator, “Clinical Trials That Might Change Your Practice” symposium, IDWeek Washington DC, 2019

Moderator, “The Etiology of Community-Acquired Pneumonia: How Appropriate are Current Guidelines?” symposium, IDWeek Washington DC, 2019

Speaker, “COVID-19: Therapies and Controversies”, an International Roundtable Discussion, August 2020

Reviewer, Research Proposal Submission, Austrian Science Fund, March 2020

Reviewer, abstract submissions, IDWeek, Infectious Diseases Society of America, October 2020

Reviewer, abstract submission, International AIDS Society, COVID-19 Prevention Conference, February 2021

Reviewer, abstract submissions, IDWeek, Infectious Diseases Society of America, October 2021

Member, Adjudication Committee, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern, South African Medical Research Council (SAMRC)

Abstract Visiting Professor, IDWeek, Infectious Diseases Society of America, October 2021

Speaker, “mRNA Vaccines Against Respiratory Viruses”, IDWEEK, Infectious Diseases Society of America, October 2022

d. Other

Member, Publications Committee, Infectious Diseases Society of America; 2014-2017

Member of the Food and Drug Administration Vaccine and Related Biological Advisory Committee; 2017-2018

Co-chair, Site Visit Review of the Laboratory of Pediatric Respiratory Viral Diseases, The Food and Drug Administration, 31 January 2018

Co-chair, Site Review Visit of the Laboratory of DNA viruses, The Food and Drug Administration, 16 May 2018

Co-Leader, National Institutes of Allergy Infectious Diseases’ Influenza Cohort Steering Committee, 2018-Present

Chair, Food and Drug Administration Vaccine and Related Biological Advisory Committee; 2019-Present

Chair, Site Visit Review of the Laboratory of hepatitis viruses and vector-borne viral diseases, The Food and Drug Administration, 25 April 2019
The Food and Drug Administration Vaccine and Related Biological Advisory Committee liaison to the National Vaccine Advisory Committee, 2019-

3. Professional Societies

Member, Infectious Diseases Society of America, 2008-Present
Member, Baylor–UTHouston Center for AIDS Research, 2010-2016

4. Elected Positions

NA

5. Invited Lectures, Presentations, Seminars

a. International

“Tuberculosis: Old and new,” Infectious Diseases Guest Speaker, American University of Beirut, August 2014

Co-moderator, “MERS-coV infections and vaccine development” symposium, IDWeek, October 2016

Moderator, “Sexually Transmitted Infections” Symposium, IDWeek San Diego, October 2017

Moderator, Oral Poster Session, “Adult Central Nervous System Infections”, IDWeek San Diego, October 2017

Moderator, “Syphilis in the 21st century” symposium, IDWeek San Francisco, October 2018

Moderator, “Tic Tac Toe: tickborne illnesses upping their game”, IDWeek Washington DC, 2019

Moderator, “Drug Resistant Gonorrhea: The Future is Here symposium”, IDWeek Washington DC, 2019

b. National

“HIV and tuberculosis”, Center for AIDS Research Guest Speaker, University of Rochester, December 2014

“Case Challenges in ID: Hepatitis and Adult Vaccinations” Pri-Med Live Webcast, October 2020

“Case Challenges in ID: STI updates”, Pri-Med Live Webcast, October 2020

“COVID-19 Vaccine Update”, CDC/IDSA COVID-19 Clinician Call, December 2020

“COVID-19 Vaccine Update”, CDC/IDSA COVID-19 Clinician Call, February 2021

“Vaccine Safety”, Podcast for the American Society for Clinical Pathology, February 2021

“COVID-19 Vaccine Efficacy Trials: The Challenge of Representation”, invited presentation at the National Foundation for Infectious Diseases 2021 Annual Conference on Vaccinology Research, April 2021

“COVID-19 vaccine efficacy studies: challenges and successes”, invited presentation at The NIH Collaboratory Grand Rounds, Duke University School of Medicine, July 2021

“Covid-19 Vaccines and Therapeutics”, Keynote Speaker, Pri-Med Southwest. April 2022

c. Regional

“Tularemia: Pathogenesis and vaccine development” Internal Medicine Grand Rounds, Baylor College of Medicine, CME accredited lecture, 2006

“Tularemia: Pathogenesis and vaccine development” Molecular Virology and Microbiology Seminar, Baylor College of Medicine, 2006

“Vaccines for adult patients infected with HIV,” Thomas Street Health Center, Houston, 2007

“HIV vaccines,” Thomas Street Health Center, Houston, 2010

“Human Vaccine Trial Network 505 HIV Vaccine Study”, Baylor–UTHouston Center for AIDS Research Seminar, February 2012

“Varicella zoster virus: treatment and prevention”, Northwest Medical Center, Medical Education Speakers Network, CME accredited lecture, Houston, July 2014

“HIV vaccine development”, Molecular Virology and Microbiology Seminar, Baylor College of Medicine, September 2014

“HIV vaccine development” Infectious Diseases Guest Presentation, The University of Texas Medical Branch at Galveston, November 2014

“Ebola virus: clinical manifestations and infection control”, Northwest Medical Center, Medical Education Speakers Network, CME accredited lecture, Houston, November 2014

“If it flu (sic) like a bird...”, Internal Medicine Grand Rounds, Baylor College of Medicine, June 2015

“Influenza: strain selection, impact of vaccination, and immunization schedules”, Internal Medicine Grand Rounds, St. Luke’s Episcopal Hospital, October 2015

“Ebola virus: clinical manifestations and vaccine development”, Internal Medicine Grand Rounds, St. Luke’s Episcopal Hospital, October 2016

“Adult Vaccinations: An update”, Northwest Medical Center, Medical Education Speakers Network, CME accredited lecture, Houston, June 2017

“Antivirals in the management of COVID-19”, Internal Medicine Grand Rounds, Baylor College of Medicine, CME accredited lecture, April 2020

“A year in COVID-19 therapeutics development” Internal Medicine Grand Rounds, Baylor College of Medicine, CME and MOC accredited lecture, December 2020

“Vaccine and therapeutics development in a pandemic” Internal Medicine Grand Rounds, Baylor College of Medicine, CME accredited lecture, September 2021

“SARS-CoV-2 Vaccines” Immunology and Microbiology Seminar Series, Baylor College of Medicine, January 2022

“Covid-19 vaccines: a lifetime in waves” 5th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference, January 2022

“Clinicopathological Conference” at The Methodist Hospital, invited discussant, April 2022

“Monkeypox Global Outbreak 2022”, AIDS Education and Training Center Program, June 2022

Moderator, 2022 Texas Vaccine Policy Symposium, Baker Institute at Rice University, October 2022

C. Publications

- (1) **El Sahly HM**, Atmar RL, Glezen WP, Greenberg SB. Spectrum of clinical illness in hospitalized patients with “common cold” virus infections. *Clin Infect Dis.* 2000;31:96-100.
- (2) Ramaswamy SV, Amin AG, Göksel S, Stager CE, Dou SJ, **El Sahly H**, Moghazeh SL, Kreiswirth BN, Musser JM. Molecular genetic analysis of nucleotide polymorphisms associated with Ethambutol resistance in human isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2000; 44:326-36.
- (3) **El Sahly HM**, Adams GJ, Soini H, Teeter L, Musser JM, Graviss EA. Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. *J Infect Dis.* 2001;183:461-8.
- (4) Ma X, Dou S, Wright JA, Reich RA, Teeter LD, **El Sahly HM**, Awe RJ, Musser JM, Graviss EA. 5’ dinucleotide repeat polymorphism of NRAMP1 and susceptibility to tuberculosis among Caucasian patients in Houston, Texas. *Int J Tuberc Lung Dis.* 2002;6:818-23.
- (5) **El Sahly HM**, Septimus E, Soini H, Septimus J, Wallace RJ, Pan X, Williams-Bouyer N, Musser JM, Graviss EA. *Mycobacterium simiae* pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. *Clin Infect Dis.* 2002;35:802-7.
- (6) **El Sahly HM**, Wright JA, Soini H, Bui TT, Williams-Bouyer N, Escalante P, Musser JM, Graviss EA. Recurrent tuberculosis in Houston, Texas: a population-based study. *Int J Tuberc Lung Dis.* 2004;8:333-40.

- (7) **El Sahly HM**. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient. *AIDS*. 2004;18:359-60.
- (8) **El Sahly HM**, Reich RA, Dou SJ, Musser JM, Graviss EA. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. *Scand J Infect Dis*. 2004;36:106-8.
- (9) Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan ISF, Wang WWB, Annunziato PW, Silber JL; Shingles Prevention Study Group (**El Sahly H** is a member of the study group). A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med*. 2005;352:2271-84.
- (10) **El Sahly HM**, Teeter LD, Pawlak RR, Musser JM, Graviss EA. Drug-resistant tuberculosis: A disease of target populations in Houston, Texas. *J Infect*. 2006;53:5-11.
- (11) **El Sahly HM**, Teeter L, Zerai T, Andrade RA, Munoz C, Nnabuiife C, Hunter R. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. *AIDS*. 2006;20:786-7.
- (12) Atmar RL, Keitel WA, Patel SM, Katz JM, She D, **El Sahly H**, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59- adjuvanted influenza A/H9N2 vaccine preparations. *Clin Infect Dis*. 2006;43:1135-42.
- (13) **El Sahly HM**, Teeter LD, Pan X, Musser JM, Graviss EA. Mortality associated with central nervous system tuberculosis. *J Infect*. 2007;55:502-9.
- (14) **El Sahly HM**, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. *Expert Rev Vaccines*. 2008;7:241-7.
- (15) **El Sahly HM**, Keitel WA. Clinical data on Fluarix®: an inactivated split seasonal influenza vaccine. *Expert Rev Vaccines*. 2008;7:713-9.
- (16) Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, **El Sahly H**, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP, Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. *JAMA* 2008;300:1532-43.
- (17) Keitel WA, Treanor JJ, **El Sahly HM**, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. *Hum Vaccines*. 2009;5:536-44.
- (18) **El Sahly HM**, Atmar RL, Patel SM, Wells JM, Cate T, Ho M, Guo K, Pasetti MF, Lewis DE, Sztein MB, Keitel WA. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. *Vaccine*. 2009;27:4905-11.
- (19) Keitel WA, Treanor JJ, **El Sahly HM**, Gilbert A, Meyer AL, Patriarca PA, Cox MM. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥ 65 years old. *Vaccine*. 2010;28:379-85.
- (20) Patel SM, Atmar RL, **El Sahly HM**, Cate TR, Keitel WA. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. *Vaccine*. 2010;28:3025-9.
- (21) **El Sahly HM**, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Sim BKL, Long C, Keitel WA. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic. *Clin Vaccine Immunol*. 2010;17:1552-9.
- (22) **El Sahly H**. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. *Expert Rev Vaccines*. 2010;9:1135-41.

- (23) **El Sahly HM**, Teeter LD, Jost KC Jr, Dunbar D, Lew J, Graviss EA. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. *J Clin Microbiol.* 2011;49:2942-5.
- (24) Bernstein DI, **El Sahly HM**, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W. Safety and immunogenicity of a candidate parvovirus B19 vaccine. *Vaccine* 2011;29:7357-63.
- (25) Treanor JJ, **El Sahly H**, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine.* 2011;29:7733-9.
- (26) **El Sahly HM**, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keitel WA. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. *J Infect Dis.* 2012;205:703-12.
- (27) Patel SM, Atmar RL, **El Sahly HM**, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. *J Infect Dis.* 2012;206:1069-77.
- (28) Keitel WA, Piedra PA, Atmar RL, Demmler G, **El Sahly HM**, Barrett J, Halpin RA, Lagos R, Fisher-Hoch S, Munoz F. Rapid research response to the 2009 A(H1N1) pdm09 influenza pandemic (Revised). *BMC Res Notes.* 2013;6:177.
- (29) McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; for the Influence65 study group (**El Sahly H** is a member of the study group). AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. *Lancet Infect Dis.* 2013;13:485-96.
- (30) Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team (**El Sahly H** is a member of the study team). Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. *N Engl J Med.* 2013;369:2083-92.
- (31) **El Sahly HM**, Teeter LD, Musser JM, Graviss EA. Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre. *Clin Microbiol Infect.* 2014;20:263-8.
- (32) Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, **El Sahly H**, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial. *Vaccine.* 2014;32:1019-28.
- (33) Callahan ST, Wolff M, Hill HR, Edwards KM, on behalf of the NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group (**El Sahly H** is a member of the study group). Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. *J Infect Dis.* 2014;210:1270-1274
- (34) Bernstein DI, Jackson L, Patel SM, **El Sahly HM**, Spearman P, Roupheal N, Rudge TL Jr, Hill H, Goll JB. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. *Vaccine.* 2014;32:6284-93
- (35) Frey SE, Bernstein DI, Brady RC, Keitel WA, **El Sahly H**, Roupheal NG, Mulligan MJ, Noah DL, Hill H, Wolff M, Belshe RB, 2009 Pandemic Vaccine Group. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. *Vaccine* 2015;33:163-73
- (36) Arasaratnam R, **El Sahly, HM**. The value of repeating CSF-VDRL during penicillin therapy to confirm the diagnosis of neurosyphilis: Four cases and a review of the literature. *Infect Dis Clin Practice* 2015;23:333-335

- (37) Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Roupael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR, for the VTEU H3N2v Vaccine Study Work Group (**El Sahly H** is a member of the Vaccine Study Group). Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A/H3N2 Variant (H3N2v) vaccine in healthy persons ≥ 18 years old. *J Infect Dis* 2015;212:552-61
- (38) El Chaer F, Harris N, **El Sahly H**, Hemmige V, Martinez Blanco E, Woc-Colburn L. Mycobacterium avium complex associated cholecystitis in AIDS patient: a case description and review of literature. *Int J STD AIDS* 2016;27:1218-1222
- (39) Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, **El Sahly H**, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Chaplin P, Belshe RB. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and the subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. *Vaccine* 2015;33:5225-34
- (40) Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech B, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, **El Sahly HM**, Hill H, Noah DL, Bellamy AR. Serologic Responses to varying dosages of a monovalent H7N9 influenza vaccine given with and without AS03 and MF59 adjuvants. *JAMA* 2015;314:237-46
- (41) Julie E. Ledgerwood, Abbie R. Bellamy, Robert Belshe, David Bernstein, Srilatha Edupuganti, Shital M. Patel, Phyllis Renehan, Thad Zajdowicz, Richard Schwartz, Richard Koup, Robert Bailer, Galina V. Yamshchikov, Mary E. Enama, Uzma Sarwar, Brenda Larkin, Barney S. Graham, and the VRC 701 study team (**El Sahly H** is a member of the study team). DNA Priming for Seasonal Influenza Vaccine: A phase 1b double-blind randomized clinical trial. *PLoS One* 2015;10:e0125914 doi:10.1371/journal.pone.0125914
- (42) Gutierrez A, **El Sahly H**. Recombinant Hemagglutinin protein vaccine: a new option in immunization against influenza. *Future Virology*: DOI:10.2217/fvl.15.75
- (43) Conrad P. Quinn, Carol L. Sabourin, Jarad M. Schiffer, Nancy A. Niemuth, Vera A. Semenova, Han Li, Thomas L. Rudge, April M. Brys, Robert S. Mittle, Chris C. Ibegbu, Jens Wrammert, Rafi Ahmed, Scott D. Parker, Janiine Babcock, Wendy Keitel, Gregory A. Poland, Harry L. Keyserling, **Hana El Sahly**, Robert M. Jacobson, Nina Marano, Brian D. Plikaytis, and Jennifer G. Wright. Humoral and Cell Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. *Clin Vaccine Immunol* 2016;23:326-38
- (44) Sen A, Katz M, Goodman JC, Gopinath SP, Woc-Colburn L, **El Sahly H**. Images in ID: persistent altered mental status in a patient with HIV. *Infectious Diseases in Clinical Practice* 2015;23:327-329
- (45) Nicolas Cortes-Penfield, Anjali Kohli, Jill Weatherhead, **Hana El Sahly**. Arcanobacterium haemolyticum CNS abscess and bacteremia following head trauma: a case report and literature review. *Infectious Diseases in Clinical Practice* 2017;25:e9-e11
- (46) John J Treanor, Laurence Chu, Brandon Essink, **Hana M El Sahly**, Ruvim Izikson, Karen Goldenthal, Peter Patriarca, Lisa M Dunkle. Stable Emulsion (SE) Alone is an Effective Adjuvant for a Recombinant, Baculovirus-Expressed H5 Influenza Vaccine in Healthy Adults: A Phase 2 Trial. *Vaccine*. 2017;35:923-928
- (47) Jackson A, Frey SE, **El Sahly HM**, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Roupael N, Hill H, Goll JB. Safety and immunogenicity of a modified Vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial. *Vaccine* 2017;35:1675-1682
- (48) **El Sahly H**, Udayamurthy M, Parkerson G, Hasbun R. Survival of an AIDS Patient after Infection with Acanthamoeba sp. of the Central Nervous System. *Infection* 2017;45:715-718
- (49) Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Roupael N, Edupuganti S, Beck A, Winokur PL, **El Sahly HM**, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary S, Pasetti MF, Szein MB, Hill H, Goll JB, and the DMID 08-0006 Tularemia Vaccine Study group. Tularemia vaccine: safety, reactogenicity, “take” skin reactions, and antibody responses following vaccination

- with a new lot of the *Francisella tularensis* Live Vaccine Strain- A phase 2 randomized clinical trial. *Vaccine* 2017;35:4730-4737
- (50) Jackson LA, **El Sahly HM**, George S, Winokur P, Edwards K, Brady RC, Roupheal N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH. Randomized Clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23 valent pneumococcal polysaccharide vaccine. *Vaccine* 2018;36:606-614
 - (51) **El Sahly HM**, Gorchakov R, Lai L, Natrajan MS, Patel SM, Atmar RL, Keitel WA, Hoft DF, Barrett J, Bailey J, Edupuganti S, Raabe V, Wu HM, Fairley J, Roupheal N, Murray KO, Mulligan MJ. Clinical, virologic and immunologic characteristics of Zika virus infection in a cohort of US patients: prolonged RNA detection in whole blood. *Open Forum Infect Dis*. 2018; 19;6(1):ofy352. doi: 10.1093/ofid/ofy352
 - (52) Allencherril J, Hammond A, Birnbaum G, Gold B, Allencherril R, Saliccioli K, **El Sahly, H**. Recrudescence of *Plasmodium falciparum* malaria in a patient with progressive sarcoidosis. *Infectious Diseases in Clinical Practice*. 2019; 27(2):102–104.
 - (53) K Connery A, Berrios-Siervo G, Arroyave P, Bauer D, Hernandez S, Paniagua-Avila A, Bolaños GA, Bunge-Montes S, **M El Sahly H**, Calvimontes M, Olson D, M Munoz F, J Asturias E.. Responding to the Zika Epidemic: Preparation of a Neurodevelopmental Testing Protocol to Evaluate Young Children in Rural Guatemala. *Am J Trop Med Hyg*. 2019;100(2):438-444.
 - (54) Gorchakov R, Berry RM, Patel SM, **El Sahly HM**, Ronca SE, Murray KO. Optimizing PCR Detection of Zika virus from various body fluids. *Am J Trop Med Hyg*. 2019;100(2):427-433.
 - (55) El Chaer F, **El Sahly H**. Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity. *Am J Med*. 2019;132(4):437-446.
 - (56) **El Sahly HM**, Atmar RL, Patel SM, Bellamy A, Liu L, Hong W, Zhu H, Guan Y, Keitel WA; DMID 13-0033 Vaccine Study Group. Safety and Immunogenicity of an 8 Year Interval Heterologous Prime-Boost Influenza A/H7N7-H7N9 Vaccination. *Vaccine*. 2019; 37(19):2561-2568
 - (57) Keitel WA, Voronca DC, Atmar RL, Paust S, Hill H, Wolff MC, Bellamy AR; VTEU H5N1 Vaccine Working Group. (Dr. **Hana El Sahly** is a member of the VTEU H5N1 Vaccine Working Group) Effect of Recent Seasonal Influenza Vaccination on Serum Antibody Responses to Candidate Pandemic Influenza A/H5N1 Vaccines: A Meta-Analysis. *Vaccine*. 2019; 37:5535-5543
 - (58) Connery AK, Colbert AM, Lamb MM, Hernández S, Martínez MA, Bauer D, Arroyave P, **El Sahly HM**, Paniagua-Avila A, Calvimontes M, Bolaños GA, Olson D, Asturias EJ, Munoz FM. Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. *Child Care Health Dev* 2019;45:702-708
 - (59) Cheema A, Mathias K, Bui C, Dunham SR, Goodman JC, **El Sahly HM**. CD8 Encephalitis in a treatment-naive and a virologically-suppressed patient with HIV. *Can J Neurol Sci*. 2019;46(6):773-775
 - (60) Keitel WA, Potter GE, Diemert D, Bethony J, **El Sahly HM**, Kennedy JK, Patel SM, Plieskatt JL, Jones W, Deye G, Bottazzi ME, Hotez PJ, Atmar RL. A Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of a *Schistosoma mansoni* Vaccine with or without Glucopyranosyl Lipid A Aqueous Formulation (GLA-AF) in Healthy Adults from a Non-Endemic Area. *Vaccine* 2019;37:6500-6509
 - (61) Lichtenberger PN, Ricciardi MJ, Solorzano D, Raccamarich P, Leda A, Sharkey M, Watkins DI, **El Sahly H**, Roupheal N, Mulligan MJ, Doblecki-Lewis S, Stevenson M, Alcaide MLOccupational exposure to the Ugandan research strain (MR766) of Zika virus.. *Open Forum Infect Dis* 2019;6(10):ofz420
 - (62) Manwani B, Xu Y, El Sahly HM. Hepatic abscesses due to *Clostridium septicum* infection and its association with colonic adenocarcinoma: a case report and literature review. *Clin J Gastroenterol*. 2020;13(1):66-72

- (63) Abate G, Stapleton JT, Roupheal N, Creech B, Stout JE, **El Sahly HM**, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaeddine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S. Variability in the Management of Adults with Pulmonary Nontuberculous Mycobacterial Disease. *Clin Infect Dis* 2020 doi: 10.1093/cid/ciaa252. Online ahead of print
- (64) Colbert, A.M., Lamb, M.M., Asturias, E.J., Muñoz, F.M., Bauer, D., Arroyave, P., Hernández, S., Martínez, A.M., Paniagua-Avila, A., Olson, D., Calvimontes, D. M., Bolaños, G.A., **El Sahly, H.M.** & Connery, A.K. Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning in Rural Guatemala. *Child: Care, Health & Dev* 2020;1-9
- (65) **Hana M. El Sahly**, George Makedonas, David Corry, Robert L. Atmar, Abbie Bellamy, Kaitlyn Cross, Wendy A. Keitel. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. *Hum Vacc Immunotherap* 2020; 13:1-8.
- (66) Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members Remdesivir for the Treatment of Covid-19 — Final Report. *New England J Med* 2020;383:1813-1826. (**Dr. El Sahly** is member of the Study Group).
- (67) Darren Harrison, Komal Muradali, **Hana El Sahly**, Biykem Bozkurt & Hani Jneid. Impact of the SARS-CoV-2 pandemic on health-care workers. *Hospital Practice*. 2020;48:161-164.
- (68) Amenta EM, Spallone A, Rodriguez-Barradas MC, **El Sahly HM**, Atmar RL, Kulkarni PA. Post-Acute COVID-19: An Overview and Approach to Classification. *Open Forum Infect Dis*. 2020 ;7(12):ofaa509.
- (69) Winokur P, **El Sahly HM**, Mulligan MJ, Frey SE, Rupp R, Anderson EJ, Edwards KM, Bernstein DI, Schmader K, Jackson LA, Chen WH, Hill H, Bellamy A; DMID 13-0034 H7N9 Vaccine Study Group.. Immunogenicity and safety of different dose schedules and antigen doses of an MF59- adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. *Vaccine*. 2021;39:1339-1348
- (70) Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, **El Sahly HM**, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Roupheal NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members.. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*. 2021 Mar 4;384:795-807
- (71) Connery AK, Lamb MM, Colbert AM, Bauer D, Hernández S, Arroyave P, Martínez MA, Barrios EE, **El Sahly HM**, Paniagua-Avila A, Calvimontes M, Bolaños GA, Olson D, Asturias EJ, Munoz FM. Parent Report of Health Related Quality of Life in Young Children in Rural Guatemala: Implementation, Reliability and Validity of the PedsQL in Stunting and Wasting. *Glob Pediatr Health*. 2021 Jan 27;8:2333794X21991028
- (72) Baden LR*, **El Sahly HM***, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupheal N, Creech CB, McGettigan J, Kehtan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384:403-416. (*primary co-authors)

- (73) Waggoner JJ, Stittleburg V, Natrajan MS, Paniagua-Avila MA, Bauer D, Olson D, **El Sahly HM**, Asturias EJ, Anderson EJ, Munoz FM.. Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. *Am J Trop Med Hyg.* 2021;104:1734-6.
- (74) Frey SE, Stapleton JT, Ballas ZK, Rasmussen WL, Kaufman TM, Blevins TP, Jensen TL, Davies DH, Tary-Lehmann M, Chaplin P, Hill H, Goll JB; DMID 09-0002 MVA Vaccine Study Group. (**Dr. El Sahly** is member of the Study Group). *J Infect Dis.* 2021;224:1372-1382.
- (75) Follmann D, Fintzi J, Fay MP, Janes HE, Baden L, **El Sahly HM**, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group is Vaccinated. *Ann Int Med.* 2021;174:1118-1125.
- (76) **El Sahly HM**, Atmar RL, Sendra E, Wegel A, Keitel WA. Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. *J Infect Dis.* 2021;224(10):1712-1719
- (77) Colombo CJ, Colombo RE, Maves RC, Branche AR, Cohen SH, Elie MC, George SL, Jang HJ, Kalil AC, Lindholm DA, Mularski RA, Ortiz JR, Tapson V, Liang CJ.; **On behalf of the ACTT-1 Study Group.** Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. (**Dr. El Sahly** is member of the Study Group) *Crit Care Explor* 2021;3(7):e0474
- (78) Colbert AM, Connery AK, Lamb MM, Bauer D, Olson D, Paniagua-Avila A, Martínez MA, Arroyave P, Hernández S, Mirella Calvimontes D, Bolaños GA, **El Sahly HM**, Muñoz FM, Asturias EJ.. Caregiver rating of early childhood development: Reliability and validity of the ASQ-3 in rural Guatemala. *Early Hum Dev.* 2021;161:105453.
- (79) **El Sahly HM***, Baden LR*, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase. *N Engl J Med* 2021;385:1774-1785.
- (80) Winokur P, **El Sahly HM**, Mulligan MJ, Frey SE, Rupp R, Anderson EJ, Edwards KM, Bernstein DI, Schmader K, Jackson LA, Chen WH, Hill H, Bellamy A; DMID 13-0034 H7N9 Vaccine Study Group. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. *Vaccine* 2021;39:1339-1348
- (81) Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, Wolfe CR, Ruiz-Palacios GM, Kline S, Regalado Pineda J, Luetkemeyer AF, Harkins MS, Jackson PEH, Iovine NM, Tapson VF, Oh MD, Whitaker JA, Mularski RA, Paules CI, Ince D, Takasaki J, Sweeney DA, Sandkovsky U, Wyles DL, Hohmann E, Grimes KA, Grossberg R, Laguio-Vila M, Lambert AA, Lopez de Castilla D, Kim E, Larson L, Wan CR, Traenkner JJ, Ponce PO, Patterson JE, Goepfert PA, Sofarelli TA, Mocherla S, Ko ER, Ponce de Leon A, Doernberg SB, Atmar RL, Maves RC, Dangond F, Ferreira J, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd L, Tomashek KM, Beigel JH; **ACTT-3 study group members.** (**Dr. El Sahly** is

member of the Study Group). Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Respir Med.* 2021;9:1365-1376

- (82) Baden LR*, **El Sahly HM***, Essink B, Follmann D, Neuzil KM, August A, Clouting H, Fortier G, Deng W, Han S, Zhao X, Leav B, Talarico C, Girard B, Paila YD, Tomassini JE, Schödel F, Pajon R, Zhou H, Das R, Miller J. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. *N Engl J Med* 2021;385:2485-2487.
- (83) Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Huynh C, Miller J, **El Sahly HM**, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA; Immune Assays Team§; Moderna, Inc. Team§; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§; United States Government (USG)/CoVPN Biostatistics Team§.. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. *Science* 2022; 375(6576):43-50.
- (84) Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, **El Sahly HM**, Essink B, Mullane KM, Frank I, Denhan D, Kerwin E, Zhao X, Ding B, Deng W, Tomassini JE, Zhou H, Leav B, Schödel F; COVE Trial Consortium. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. *Nat Med* 2022;28:823-830
- (85) Akamine CM, **El Sahly HM**. Messenger Ribonucleic Acid Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2 – A Review. *Transl Res.* 2022 242:1-19
- (86) Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, **El Sahly HM**, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Homologous and Heterologous Covid-19 Booster Vaccinations. *N Engl J Med* 2022;386(11):1046-1057
- (87) Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore KM, Floyd K, Foster SL, Posavad CM, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Sullivan NJ, Roberts PC, Beigel JH, Korber B, Baden LR, **El Sahly H**, Chalkias S, Zhou H, Feng J, Girard B, Das R, Aunins A, Edwards DK, Suthar MS, Mascola JR, Montefiori DC. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. *N Engl J Med* 2022;386(11):1088-1091
- (88) Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; **2019nCoV-301 Study Group. (Dr. El Sahly is member of the Study Group)**. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *N Engl J Med.* 2022;386:531-543

- (89) Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, Yang OO, Paules CI, Palacios GMR, Grossberg R, Harkins MS, Mularski RA, Erdmann N, Sandkovsky U, Almasri E, Pineda JR, Dretler AW, de Castilla DL, Branche AR, Park PK, Mehta AK, Short WR, McLellan SLF, Kline S, Iovine NM, **El Sahly HM**, Doernberg SB, Oh MD, Huprikar N, Hohmann E, Kelley CF, Holodniy M, Kim ES, Sweeney DA, Finberg RW, Grimes KA, Maves RC, Ko ER, Engemann JJ, Taylor BS, Ponce PO, Larson L, Melendez DP, Seibert AM, Rouphael NG, Strebe J, Clark JL, Julian KG, de Leon AP, Cardoso A, de Bono S, Atmar RL, Ganesan A, Ferreira JL, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd LE, Beigel JH, Kalil AC; ACTT-4 Study Group. Baricitinib versus Dexamethasone for Hospitalized Adults with COVID-19. *Lancet Respir Med* 2022; 10(9):888-899
- (90) Connery, A.K.*, Lamb, M.M*, Colbert, A.M., Bauer, Desirée, Olson, Daniel, Paniagua-Avila, Alejandra, Calvimontes, Mirella, Bolaños, Guillermo Antonio, **El Sahly, Hana**, Muñoz, F.M.***, Asturias, E.J.** (2022). A Prospective Cohort Study of Head Circumference and its Association with Neurodevelopmental Outcomes in Infants and Young Children in Rural Guatemala. *J Dev Orig Health Dis.* 2022; Apr 22;1-8
- (91) Fintzi J, Bonnett T, Tebas P, Marconi VC, Levine CB, **El Sahly HM**, McLellan SLF, Benson CA, Rostad CA, Ganesan A, Huprikar N, Frank MG, Mularski RA, Atmar RL, Park PK, Short WR, Beigel JH, Mehta AK, Sweeney DA Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. *Open Forum Infect Dis.* 2022 Apr 27;9(7):ofac219
- (92) Lin DY, Baden LR, **El Sahly HM**, Essink B, Neuzil KM, Corey L, Miller J; COVE Study Group. Durability of Protection for the mRNA-1273 SARS-CoV-2 Vaccine. *JAMA Netw Open* 2022;5(6):e2215984.
- (93) **El Sahly HM**, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Schödel F, Das R, August A, Leav B, Miller JM, Zhou H, Pajon R; Coronavirus Efficacy (COVE) Study Group. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial. *J Infect Dis.* 2022; 226(10):1731-1742.
- (94) Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, Finkelstein D, Pickrell P, Kirstein J, Yut C, Blair R, Clifford RA, Dunn M, Campbell JD, Montefiori DC, Tomassini JE, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. (**Dr. El Sahly** is member of the Study Group). *N Engl J Med* 2022;386:2011-2023
- (95) Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdury R, Deming ME, Eaton A, Jackson LA, Branche AR, **El Sahly HM**, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Archer JJ, Crandon S, Zemanek JA, Brown ER, Neuzil KM, Stephens DS, Post DJ, Nayak SU, Suthar MS, Roberts PC, Beigel JH, Montefiori DC; DMID 21-0012 Study Group. Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant. *Cell Rep Med* 2022; 3(7):100679.
- (96) Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, **El Sahly HM***, Baden LR*. Anti-nucleocapsid antibodies following SARS-

CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 Covid-19 vaccine efficacy clinical trial. *Ann Intern Med* 2022;175(9):1258-1265 (* co-senior authors)

- (97) Lamb MM, Connery AK, Colbert AM, Bauer D, Olson D, Paniagua-Avila A, Calvimontes DM, Bolaños GA, **Sahly HME**, Muñoz FM, Asturias EJ. Anthropometric Proxies for Child Neurodevelopment in Low Resource Settings: Length- or Height-for-Age, Head Circumference or Both? *J Dev Origins Heal Dis* 2023; 14(1):61-69
- (98) Wang G, Stapleton JT, Baker AW, Roupshael N, Creech CB, **El Sahly HM**, Stout JE, Jackson L, Charbek E, Leyva FJ, Tomashek KM, Tibbals M, Miller A, Frey S, Niemotka S, Wiemken TL, Beydoun N, Alaaeddine G, Turner N, Walter EB, Chamberland R, Abate G. Clinical features and treatment outcomes of pulmonary Mycobacterium avium-1 intracellulare complex with and without co-infections. *Open Forum Infect Dis* 2022 Jul 26;9(8):ofac375
- (99) Siangphoe U, Baden LR, **El Sahly HM**, Essink B, Ali K, Berman G, Tomassini JE, Deng W, Pajon R, McPhee R, Dixit A, Das R, Miller JM, Zhou H; COVE and TeenCOVE Study Groups. Associations of Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA-1273 Vaccine in COVE and TeenCOVE Trials. *Clin Infect Dis* 2023;76(2):271-280.
- (100) Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, Garner F, Griffin C, Palanpurwala K, Turner M, Gerber J, Bennett RL, Ali K, Ampajwala M, Berman G, Nayak J, Chronis C, Rizzardi B, Muller WJ, Smith CA, Fuchs G, Hsia D, Tomassini JE, DeLucia D, Reuter C, Kuter B, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Aunins A, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group.. (**Dr. El Sahly** is member of the Study Group). *New Engl J Med* October 19, 2022;387(18):1673-1687
- (101) Tsalik EL, Roupshael NG, Sadikot RT, Rodriguez-Barradas MC, McClain MT, Wilkins DM, Woods CW, Swamy GK, Walter EB, **El Sahly HM**, Keitel WA, Mulligan MJ, Tuyishimire B, Serti E, Hamasaki T, Evans SR, Ghazaryan V, Lee MS, Lautenbach E; TRAP-LRTI Study Group; Antibacterial Resistance Leadership Group. Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. *Lancet Infect Dis* 2022; S1473-3099(22)00735-6.
- (102) Paniagua-Avila A, Olson D, Connery A, Calvimontes DM, Bolanos GA, Lamb MM, Bauer D, Ralda A, Rojop N, Barrios E, Chacon A, Gomez M, Arroyave P, Hernandez S, Martinez MA, Bunge-Montes S, Colbert A, Arias K, Brazeale G, Holliday A, Tomashek KM, **El Sahly HM**, Keitel W, Munoz FM, Asturias EJ. Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. *PLoS Negl Trop Dis* 2022;16(11):e0010480.
- (103) Mena Lora AJ, Long JE, Huang Y, Baden LR, **El Sahly HM**, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Roupshael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 Covid-19 Vaccine Trials. *JAMA Netw Open* 2023 Jan 3;6(1):e2251974
- (104) Acosta CJ, Diaz C, Nordio F, Han HH, Moss KJ, Bohning K, Kumar P, Liu M, Patel H, Pacciarini F, Mwangi V, Walter E, Powell TD, **El Sahly HM**, Baldwin WR, Santangelo J, Anderson EJ, Dubin G. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in

Healthy Adults: 2 Years of Follow-Up Compared With Natural Infection. *J Infect Dis* 2022 Dec 9;jiac482. doi: 10.1093/infdis/jiac482. Online ahead of print.

- (105) Kathleen M. Neuzil, Evan J. Anderson, Robert W. Frenck, Sharon E. Frey, Emmanuel B. Walter, Richard Rupp, Elizabeth T. Rostrosen, Nadine G. Roupheal, Rebecca C. Brady, Irene Graham, Kenneth E. Schmader, Laura Portfield, Justin R. Ortiz, Geeta K. Swamy, **Hana M. El Sahly**, Trushar Jeevan, Ranjan Sitaula, Ashley Wegel, Richard J. Webby, Christopher Bryant, on behalf of the Influenza A/H5N8 Virus Vaccine Group. Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine given With or Without AS03 or MF59 Adjuvants. *Clin Infect Dis* (in press)
- (106) Patricia L Winokur, Theresa E Hegmann, Wendy A Keitel, David I Bernstein, Sharon E Frey, Chris Bryant, DMID 15-0064 Study Group (**Dr. El Sahly** is member of the Study Group). Safety and Immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults. *Clin Infect Dis* (in press)
- (107) Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryanny L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, Neuzil KM, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, **El Sahly HM**. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. *Open Forum Infect Dis*. 2023 Feb 13;10(3):ofad069
- (108) Ortiz JR , Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, Brady RC, Bryant C, Wegel W, Frenck RW, Walter EB, Abate G, Williams SR, Atmar RL, Keitel WA, Roupheal R, Memoli MJ, Makhene MK, Roberts PC, Neuzil KM; Influenza Controlled Human Infection Study Group Members. (Dr. **El Sahly** is member of the Study Group). A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults. *J Infect Dis*: 2023;228(3):287-298.
- (109) Robert L. Atmar, David I. Bernstein, Patricia Winokur, Sharon E. Frey, Laura S. Angelo, Christopher Bryant, Tammy Ben-Yedidia, Paul C. Roberts, **Hana M. El Sahly**, Wendy A. Keitel. Safety and Immunogenicity of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Inactivated Influenza Vaccine in Young Adults. *Vaccine* (in press)
- (110) David J. Diemert, Rodrigo Correa-Oliveira, Carlo Geraldo Fraga, Frederico Talles, Marcella Rezende, Shital Patel, Shirley Galbiati, Jessie K Kennedy, Jordan S. Lundeen, Maria Flavia Gazzinelli, Guangzhao Li, Lara Hoeweler, Gregory A. Deye, Maria Elena Bottazzi, Peter Hotez, **Hana M. El Sahly**, Wendy A. Keitel, Jeffrey Bethony, Robert L. Atmar. A Randomized, Controlled Phase 1b Trial of the Sm-TSP-2 Vaccine for Intestinal Schistosomiasis in Healthy Brazilian Adults Living in an Endemic Area. *PLoS Neglect Trop Dis* (in press)
- (111) Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Williamson BD, Garver J, Altonen E, Rudge T, Huynh C, Miller J, **El Sahly HM**, Baden LR, Frey S, Malkin E, Spector SA, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB; Immune Assays; Moderna Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); United States Government (USG)/CoVPN Biostatistics Teams. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. *Sci Transl Med*. 2023;15(692):eade9078

- (112) Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, **El Sahly HM**, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT Jr, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM.. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case. *Open Forum Infect Dis*. 2023 May 27;10(6):ofad290.
- (113) Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, **El Sahly HM**, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Cohen. Examining Protective effects of SARS-CoV-2 Neutralizing antibodies after vaccination or monoclonal antibody administration. *Nat Commun* 2023 Jun 17;14(1):3605
- (114) Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR*, **El Sahly HM***, Sobieszczyk ME*, Huang Y*; COVID-19 Prevention Network (CoVPN). Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis. *JAMA Netw Open* 2023 Jul 3;6(7):e2323349 * contributed equally
- (115) Olson D, Lamb MM, Connery AK, Colbert AM, Calvimontes DM, Bauer D, Paniagua-Avila MA, Martínez MA, Arroyave P, Hernandez S, Colborn KL, Roell Y, Waggoner JJ, Natrajan MS, Anderson EJ, Bolaños GA, **El Sahly HM**, Munoz FM, Asturias EJ. Cumulative Febrile, Respiratory, and Gastrointestinal Illness among Infants in Rural Guatemala and Association with Neurodevelopmental and Growth Outcomes. *Pediatr Infect Dis J*. 2023 Sep 1;42(9):739-744
- (116) Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, **El Sahly HM**, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Roupheal N, Szydlo D, Paul Choudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryanny L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 Heterologous Boost Against SARS-CoV-2 Variants. *NPJ Vaccines*. 2023 Jul 11;8(1):98.
- (117) Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, **El Sahly HM**, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Roupheal N, Luedtke A; COVID-19 Prevention Network CoVPN.. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials. *Vaccine*. 2023 Jul 25;41(33):4899-4906
- (118) Jennifer A. Whitaker; **Hana M. El Sahly**; C. Mary Healy. mRNA Vaccines against Respiratory Viruses. *Curr Op Infect Dis* (in press)
- (119) **Hana M. El Sahly**, Inci Yildirim, Sharon E. Frey, Patricia Winokur, Lisa A. Jackson, David I. Bernstein, C. Buddy Creech, Wilbur H. Chen, Richard E. Rupp, Jennifer A. Whitaker, Varun Phadke, Daniel F. Hoft, Dilek Ince, Rebecca C. Brady, Kathryn M. Edwards, Justin R. Ortiz, Megan A. Berman, Julia Weiss, and Ashley Wegel, on behalf of the DMID 17-0090 Study Group. Safety

and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. *J Infect Dis* (in press)

- (120) Angela R. Branche*, Nadine G. Rouphael*, David J. Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Evan J. Anderson, Emmanuel B. Walter, Richard M. Novak, Richard Rupp, Lisa A. Jackson, Tara M. Babu, Angelica C. Kottkamp, Anne F. Luetkemeyer, Lilly C. Immergluck, Rachel M. Presti, Martin Bäcker, Patricia L. Winokur, Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco, Elissa Malkin, Jeffrey M. Bethony, Edward E. Walsh, Daniel S. Graciaa, Hady Samaha, Amy C. Sherman, Stephen R. Walsh, Getahun Abate, Zacharoula Oikonomopoulou, **Hana M. El Sahly**, Thomas C.S. Martin, Christina A. Rostad, Michael J. Smith, Benjamin G. Ladner, Laura Porterfield, Maya Dunstan, Anna Wald, Tamia Davis, Robert L. Atmar, Mark J. Mulligan, Kirsten E. Lyke, Christine M. Posavad, Megan A. Meagher, David S. Stephens, Kathleen M. Neuzil, Kuleni Abebe, Heather Hill, Jim Albert, Teri C. Lewis, Lisa A. Giebeig, Amanda Eaton, Antonia Netzl, MSc31; Samuel H. Wilks, Sina Türeli, Mamodikoe Makhene, Sonja Crandon, Marina Lee, Seema U. Nayak, David C. Montefiori, Mat Makowski, Derek J. Smith, Paul C. Roberts*, John H. Beigel*. Bivalent and Monovalent Variant Vaccines Improve coverage of the SARS-CoV-2 Antigenic Landscape: Results from the phase 2 randomized open-label COVAIL Trial. *Nat Med* (in press)
- (121) Christopher S. Eickhoff, Krystal A. Meza, Frances E. Terry, Chase G. Colbert, Azra Blazevic, Andres H. Gutiérrez, E. Taylor Stone, James D. Brien, Amelia K. Pinto, **Hana M. El Sahly**, Mark J. Mulligan, Nadine Rouphael, Maria L. Alcaide, Walla Dempsey, Kay M. Tomashek, Chris Focht, William D. Martin, Leonard Moise, Anne S. De Groot, and Daniel F. Hoft. Identification of immunodominant T cell epitopes induced by natural Zika virus infection. *Front Immunol* (in press)
- (122) Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, Suthar MS, Coler RN, Berube BJ, Kim SH, Piper JM, Miller AM, Cardemil CV, Neuzil KM, Beigi RH; DMID 21-0004 Study Group. (**Dr. El Sahly is a member of the Study Group**). COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. *Vaccine*. 2023;41(36):5296-5303
- (123) Nima S. Hejazi, Xiaoying Shen, Lindsay N. Carpp, David Benkeser, Dean Follmann, Holly E. Janes, Lindsey R. Baden, **Hana M. El Sahly**, Weiping Deng, Honghong Zhou, Brett Leav, David C. Montefiori, Peter B. Gilbert. Stochastic Interventional Approach to Assessing Immune Correlates of Protection: Application to the COVE mRNA-1273 Vaccine Trial. *Int J Infect Dis* (in press)
- (124) Anne-Marie Rick, Matthew B. Laurens, Ying Huang, Chenchen Yu, Thomas C.S. Martin, Carina A. Rodriguez, Christina A. Rostad, Rebone M. Maboja, Lindsey R. Baden, **Hana M. El Sahly**, Beatriz Grinsztejn, Glenda E. Gray, Cynthia L. Gay, Peter B. Gilbert, Holly E. Janes, James J. Kublin, Yunda Huang, Brett Leav, Ian Hirsch, Frank Struyf, Lisa M. Dunkle, Kathleen M. Neuzil, Lawrence Corey, Paul A. Goepfert, Stephen R. Walsh, Dean Follmann, Karen L. Kotloff. Risk of COVID-19 after natural infection or vaccination. *eBioMedicine*. 2023;96:104799
- (125) Ying Huang, Nima S. Hejazi, Bryan Blette, Lindsay N. Carpp, David Benkeser, David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly E. Janes, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen A. Martins, Lakshmi Jayashankar, Britta Flach, Bob C. Lin, Sarah O'Connell, Charlene McDanal, Amanda Eaton, Marcella Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Avi Kenny, Marco Carone, Chuong Huynh, Jacqueline Miller, **Hana M. El Sahly**, Lindsey R. Baden, Lisa A. Jackson, Thomas B. Campbell, Jesse L Clark, Michele Peake Andrasik, James G.

Kublin, Lawrence Corey, Kathleen M. Neuzil, Rolando Pajon, Dean A. Follmann, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert. Stochastic interventional vaccine efficacy and principal surrogate effect modification analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial. *Viruses* (in press)

- (126) Daanish Sheikh; Kristen A. Stagers; Jennifer Carey; Wendy A. Keitel; Robert L. Atmar; **Hana M. El Sahly**; Jennifer A. Whitaker. Delays in hepatitis B immunization series completion in people with HIV. *Open Forum in Infectious Diseases* (in press)

2. Full Papers without Peer Review

a. Published

- (1) **El Sahly HM**, Soini H, Graviss EA. Drug resistant tuberculosis- review article. *BioMedicina*. 2000;3:137-42.
- (2) Weatherhead J, **El Sahly H**. Coccidioidomycosis as a cause of small bowel perforation: a case report. *J Clin Gastroenterology* 2015;49:628-629.

b. In Preparation

- (1) Vivek Shinde, Pedro Piedra, Edward Belongia, Iksung Cho, D. Nigel Thomas, Kirsten Carroll, Hanxin Lu, Bin Zhou, Dewal Jani, **Hana El Sahly**, Joyce Plested, Huong Q McLean, Jennifer Meece, Sapeckshita Agrawal, Lisa Jackson, Louis Fries, Gregory Glenn. A tale of two trials: RSV F Vaccine for the Prevention of RSV Disease in Older Adults. Submitted

3. Abstracts Given During Last Three Years

- (1) Desirée Bauer, Amy K. Connery, Molly M. Lamb, Alejandra Paniagua-Avila, Alison M. Colbert, Sara Hernández, Paola Arroyave, Maria Alejandra Martínez, Paola Arroyave, Alejandra Paniagua-Avila, Mirella Calvimontes, Guillermo A. Bolaños, Daniel Olson, Hana M. El Sahly, Flor M. Muñoz and, Edwin J. Asturias. Relationship Between Stunting and Neurodevelopment of Young Children in Rural Guatemala. Consortium of Universities for Global Health Annual Conference, Washington, DC, 2020
- (2) Molly M. Lamb, Amy K. Connery, Alison M. Colbert, Desiree Bauer, Daniel Olson, Alejandra Paniagua-Avila, Paola Arroyave, Sara Hernandez, Maria A. Martinez, Andrea Holliday, Hana M. El Sahly, Flor M. Munoz, Edwin J. Asturias. Testing Different WHO Head Circumference Z-Score Cutoffs for Association with Neurodevelopmental Outcomes in Infants and Young Children in Rural Guatemala. Annual Meeting of the American Society of Tropical Medicine and Hygiene, 2020
- (3) Olson D, Lamb MM, Connery AK, Bauer D, Paniagua-Avila MA, Colborn KL, Natrajan MS, Waggoner J, Anderson EJ, Calvimontes M, Bolaños GA, Pettibone S, El Sahly HM, Munoz FM, Asturias EJ. Association between cumulative febrile, respiratory and diarrheal illness in the first year of life and neurodevelopmental and growth outcomes among a cohort of children in rural Guatemala. Poster Presentation. Philadelphia, PA. 2020.
- (4) Munoz FM, Lamb MM, Waggoner J, Bauer D, Paniagua-Avila MA, Connery AK, Olson D, Natrajan MS, Anderson EJ, Calvimontes M, Bolaños GA, El Sahly HM, Asturias EJ. Cytomegalovirus (CMV) infection in the first year of life in a cohort of infants in rural Guatemala. IDWeek. Philadelphia, PA. 2020.
- (5) Emily T. Ciocca, Kristen A. Stagers, Jennifer Carey, Antone Opekun, F. B. Hollinger, Wendy A. Keitel, **Hana M. El Sahly**, Robert L. Atmar, Jennifer Whitaker. Retrospective study of hepatitis

A immunization rates in persons with HIV. Conference on Retroviruses and Opportunistic Infections (CROI) 2021. Science Spotlight™ Presentation.

- (6) Camilo J. Acosta, Clemente Diaz, Francesco Nordio, Htay-Htay Han, Kelley J. Moss, Kelly Bohning, Pradeep Kumar, Mengya Liu, Hetal Patel, Filippo Pacciarini, Vincent Mwangi, Elke Walter, Hana M. El Sahly, Whitney Baldwin, Joe Santangelo, Evan J. Anderson, Gary Dubin. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: Two Years Follow-up Compared With Natural Infection. Northern European Conference on Travel Medicine, Rotterdam 2022
- (7) Tyler Brehm, Richard Hamill, Rodrigo Hasbun, **Hana M. El Sahly**. Central Nervous system histoplasmosis: a retrospective review of clinical characteristics, treatments, and outcomes. American College of Physicians Annual meeting, San Diego April 2023
- (8) Bethany Girard, **Hana M. El Sahly**, Lindsey R. Baden, Brandon Essink, Avika Dixit, Frances Priddy, Yoonyoung Park, Mollie Brown, Honghong Zhou, Xiaowei Wang, Joanne E. Tomassini, Jacqueline Miller, Rituparna Das. Detection of Respiratory Pathogens in the COVE Trial. The 33rd European Congress of Clinical Microbiology & Infectious Diseases, Copenhagen April 2023
- (9) Avika Dixit, Lindsey R. Baden, **Hana M. El Sahly**, Brandon Essink, Frances Priddy, Honghong Zhou, Xiaowei Wang, Mollie Brown, Bethany Girard, Joanne E. Tomassini, Dina Stolman, Andrea Sutherland, Florian Schödel, Jacqueline Miller, Rituparna Das. Safety and Effectiveness of the mRNA-1273 Booster in the COVE Trial. The 33rd European Congress of Clinical Microbiology & Infectious Diseases, Copenhagen April 2023
- (10) Jennifer A. Whitaker, Paulina Rebolledo, Nadine Rouphael, Getahun Abate, Tara Babu, Anna Wald, **Hana El Sahly**, Pedro Garbes, Karin Jooss, Andrew Allen, Lisa McQuarrie, Ranjan Sitaula, Paul C. Roberts, Mamodikoe Makhene, Christin Posavad, Juliana McElrath, Stephen De Rosa, Thea Coler, David Montefiori, Amanda Eaton, David Koelle, Daniel Hoft. An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults. IDWeek, Boston 2023
- (11) Dean Follmann, Xiaowei Wang, Peter Gilbert, Lindsey R Baden, **Hana M. El Sahly**, Brandon Essink, Holly E Janes, Mary Marovich, Weiping Deng, Frances Priddy, Avika Dixit, Joanne E Tomassini Rituparna Das, Jacqueline Miller, Honghong Zhou. Who to boost when: an analysis of dosing interval and age on Covid-19 outcomes in the COVE trial during the Delta and Omicron Waves, Oral abstract, Late Breaker, IDWeek, Boston 2023

4. Books

NA

5. Other Works Communicating Research Results to Scientific Colleagues

- (1) Monthly Contributor, Practical Reviews in Infectious Diseases; 2009-2012
- (2) El Sahly HM. Performance of Xpert MTB/RIF in induced sputum samples at detecting Mycobacterium Tuberculosis. (Letter to the Editor). Clin Infect Dis. 2014;59:911-2.

6. Other Works Communicating Research Results to General Public

- (1) El Sahly, H. "The challenge remains: a way to prevent AIDS." Opinion article in The Houston Chronicle, 01 December 2010
- (2) El Sahly, H. Health on Campus and Sexually Transmitted Diseases. Lecture to International Students at Aramco, Houston, Texas. February 2007

- (3) El Sahly, H. “Can HVTN505 vaccine prevent HIV infection?” From Research to the Real World: Sharing Science Symposium, sponsored by the Baylor–UT Houston Center for AIDS Research and the Houston Department of Health and Human Services, 2014
- (4) Numerous interviews with local and national media outlets regarding influenza and HIV infection.
- (5) “Unite to End TB: What it means for me in 2016”, Houston Exxon Mobile Awareness campaign, panel member
- (6) El Chaer F, El Sahly M. Reply to Comments on “Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity”. Am J Med. In press.

D. Innovation and Commercialization

NA

III. TEACHING INFORMATION

A. Educational Leadership Roles (title, dates, responsibilities)

B. Didactic Coursework

1. Courses Taught at Current Institution (include number of hours)

Lecturer, Microbial Pathogenesis course, every other year, 1 hour (2009)

Lecturer, Medical Students Infectious Diseases Module, annual, 6 hours (2007-Present)

Lecturer, Fellows Core Curriculum, annual, 1 hour (2007-Present)

Lecturer, Intensive Course in Travel and Tropical Medicine, annual, 3 hours (2008-2011)

Lecturer, Diploma in Tropical Medicine, twice a year, 3 hours each (2012-2017) and 2 hours each (2020-Present)

Lecturer, AIDS Readings, once a year, 1 hour (2015-Present)

Co-Coordinator, Journal Club in Vaccine Development, Translational Biology and Molecular Medicine Program (2008)

Lecturer, Vaccinology, once a year, 2 hours each (2021-Present)

Associate-director, Infectious Diseases Module for BCM medical students, BCM (2014-2022)

C. Curriculum Development Work (include institution where work was done and whether work was disseminated beyond home institution)

NA

D. Non-didactic Teaching (include institution where work was done)

1. Resident and fellow clinical training: Dr. El Sahly is attending physician at Ben Taub General Hospital and Thomas Street Health Center, which occupies 36% of her time. Infectious Diseases fellows and Internal Medicine residents are always present in these locations and Dr. El Sahly supervises the trainees and performs clinical education responsibilities.
2. Medical Content Expert, Eisenberg Center: “Interventions to Improve Appropriate Antibiotic Use for Acute Respiratory Tract Infection” (2015)
3. Thesis Advisory Committee:
 - a. Ben Hornstein (2014-2017)
 - b. Shubhranshu Gupta (2015-2020)
4. Clinical Mentor: Translational Biology and Molecular Medicine Program
 - a. Shubhranshu Gupta (2015-)
5. Member of the Research Committee:
 - a. Erin Nicholson, MD, Faculty, Department of Pediatrics, Section of Infectious Diseases, BCM (2018-Present)

6. Mentor, National Institutes of Health, Division of Microbiology and Infectious Diseases Mentorship Pilot Program.
 - a. Jonathan McNeil, MD, Faculty, Department of Pediatrics, Section of Infectious Diseases (2018-2020)

E. Faculty Development or Continuing Medical Education (list contributions as a course developer, presenter, etc.)

NA

F. Lectures and Presentations (provide complete citation for each item; list invited lectures in II.B.5 and lectures, posters or presentations with published abstracts in section II.C.3)

“Muffins with Mentors”, Center for Professionalism at Baylor College of Medicine, October 2023

G. Visiting Professorships (include location, dates)

“New Vaccines for an Old Virus: Respiratory Syncytial Virus” The Seventh Annual Daniel Musher, MD Visiting Professor Lecture, September 2023

IV. PATIENT CARE AND CLINICAL CONTRIBUTIONS

A. Patient Care Responsibilities

1. Attending Physician at Thomas Street Health Center, outpatient HIV care, Section of Infectious Diseases at the Department of Medicine, 2001-2020
2. Attending physician, Ben Taub Hospital, General Infectious Diseases and Immunocompromised Services, Section of Infectious Diseases at the Department of Medicine, 2005-Present.

B. Clinical Leadership or Business Development (describe roles and documented outcomes)

NA

C. Voluntary Health Organization Participation

NA

D. Contributions, Initiatives or Recognition Related to Patient Safety and Healthcare Quality (include information about implementation, outcomes or dissemination, where applicable)

NA

E. Contributions to Health and Science Policy (institutional, regional, state, or federal level)

V. SERVICE CONTRIBUTIONS

A. Administrative Assignments and Committees

1. Department Administration, Committees
 - a. Judge, Annual House Staff Research Symposium, Department of Medicine, 2010-Present
 - b. Judge, MVM Department Annual Research Retreat, Baylor College of Medicine, 2013, 2014
 - c. Judge, Graduate Student Research Symposium, 2011, 2018
 - d. Judge, Medical Students Research Symposium, 2014, 2016, 2018
 - e. Judge, BCM Translational Biology and Molecular Medicine Annual Retreat, 2018
 - f. Member, Faculty Appointments and Promotions Committee, Department of Medicine 2017-Present

2. Institution-wide or School Administration, Committees, etc.
 - a. Member, Medical School Admissions Committee, 2009-2014

- b. Member, Institutional Review Board at Baylor College of Medicine, 2007-2017
- c. Member, Infectious Diseases Section Chief Search Committee, 2017
- d. Member, Infectious Diseases Research Faculty Search Committee, 2020

B. National, Regional or Local Participation in Professional or Voluntary Organizations

C. Other Pertinent Information (not given above, including community service)

- 1. Panelist: “Women Scientist in the fight against COVID-19”: a program organized on the margins of the 65th Session of the Commission of the Status of Women at the United Nations.